Top

Published in:

Open Access 23-01-2024 | Simvastatin | Research

Simvastatin Significantly Reduced Alcohol-Induced Cardiac Damage in Adolescent Mice

Authors: Makgotso Nchodu, Alice Efuntayo, Robin du Preez, Hasiena Ali, Oladiran I. Olateju

Published in: Cardiovascular Toxicology | Issue 1/2024

Abstract

Alcohol abuse by adolescents is becoming a serious health concern as they often progress to becoming alcoholics later in life which may lead to heart problems. Chronic alcohol use alters the cardiac function and structure, such as haemodynamic changes, weakening and loss of cardiomyocytes, myocardial fibrosis, and inflammation. Simvastatin is a commonly used drug for the treatment and management of various cardiovascular problems but information on its protective effects against alcohol-induced cardiomyocyte hypertrophy, fibrosis, and inflammation is lacking in the literature. Four-week-old male (n = 5) and female (n = 5) C57BL/6 J mice were assigned to each experimental group: (I) NT—no administration of alcohol or Simvastatin; (II) ALC—2.5 g/Kg/day of 20% alcohol via intraperitoneal injection (i.p.); (III) SIM—5 mg/Kg/day of Simvastatin via oral gavage; (iv) ALC + SIM5—5 mg/Kg/day of Simvastatin via oral gavage followed by 2.5 g/Kg/day of 20% alcohol via i.p.; and (v) ALC + SIM15—15 mg/Kg/day Simvastatin via oral gavage followed by 2.5 g/Kg/day of 20% alcohol via i.p. After the 28-day treatment period, the heart was removed and processed for H&E, Masson’s trichrome, or TNF-α immunolabelling. The area and diameter of cardiomyocytes were measured on the H&E-stained sections. The distribution of collagen or TNF-α expression was quantified using the deconvolution tool of ImageJ software. The results confirmed alcohol-induced toxicity on the cardiomyocytes and Simvastatin reduced alcohol-induced cardiomyocyte hypertrophy, fibrosis, and inflammation in both sexes. This study demonstrated that Simvastatin, an FDA approved and easily accessible drug, may be beneficial in lowering the prevalence of alcohol-induced cardiovascular diseases (especially in adolescents) which will have a huge financial implication on health systems worldwide.

Available only for authorised users

Marshall, E. J. (2014). Adolescent alcohol use: Risks and consequences. Alcohol and Alcoholism, 49(2), 160–164. https://doi.org/10.1093/alcalc/agt180CrossRefPubMed

Ramsoomar, L., Morojele, N. K., & Norris, S. A. (2013). Alcohol use in early and late adolescence among the birth to twenty cohort in Soweto. South Africa. Global Health Action, 6(1), 57–66. https://doi.org/10.3402/gha.v6i0.19274CrossRef

Olsson, C. A., Romaniuk, H., Salinger, J., Staiger, P. K., Bonomo, Y., Hulbert, C., & Patton, G. C. (2016). Drinking patterns of adolescents who develop alcohol use disorders: Results from the Victorian Adolescent Health Cohort Study. British Medical Journal Open, 6(2), 1–10. https://doi.org/10.1136/bmjopen-2015CrossRef

Matzopoulos, R. G., Truen, S., Bowman, B., & Corrigall, J. (2014). The cost of harmful alcohol use in South Africa. South African Medical Journal, 104(2), 127–132. https://doi.org/10.7196/SAMJ.7644CrossRefPubMed

Swart, L. A., Seedat, M., & Nel, J. (2015). Alcohol consumption in adolescent homicide victims in the city of Johannesburg. South Africa. Addiction, 110(4), 595–601. https://doi.org/10.1111/add.12825CrossRefPubMed

Bertscher, A., London, L., & Röhrs, S. (2020). A human rights analysis of South Africa’s control of marketing of alcoholic beverages bill. International Journal on Human Rights and Business, 4, 1–27.

Obad, A., Peeran, A., Little, J. I., Haddad, G. E., & Tarzami, S. T. (2018). Alcohol-mediated organ damages: Heart and brain. Frontiers in Pharmacology, 9(81), 1–15. https://doi.org/10.3389/fphar.2018.00081CrossRef

Piano, M. R. (2017). Alcohol’s effects on the cardiovascular system. Alcohol Research, 38(2), 219–241.PubMedPubMedCentral

Fernández-Solà, J. (2020). The effects of ethanol on the heart: Alcoholic cardiomyopathy. Nutrients, 12(572), 1–18. https://doi.org/10.3390/nu12020572CrossRef

10.

Wang, L., Zhou, Z., Saari, J. T., & Kang, Y. J. (2005). Alcohol-induced myocardial fibrosis in metallothionein-null mice prevention by zinc supplementation. American Journal of Pathology, 167(2), 337–344. https://doi.org/10.1016/S002-9440(10)62979-3CrossRefPubMedPubMedCentral

11.

Schumacher, S. M., & Naga Prasad, S. V. (2018). Tumor necrosis factor-α in heart failure: an updated review. Current Cardiology Reports, 20(11), 1–18. https://doi.org/10.1007/s11886-018-1067-7CrossRef

12.

Bryant, D., Becker, L., Richardson, J., Shelton, J., Franco, F., Peshock, R., Thompson, M., & Giroir, B. (1998). Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor. Circulation, 97(14), 1375–1381. https://doi.org/10.1161/01.cir.97.14.1375CrossRefPubMed

13.

Gao, K., Wang, G., Wang, Y., Han, D., Bi, J., Yuan, Y., Yao, T., Wan, Z., Li, H., & Mei, X. (2015). Neuroprotective effect of simvastatin via inducing the autophagy on spinal cord injury in the rat model. BioMed Research International, 2015(2), 1–9. https://doi.org/10.1155/2015/260161CrossRef

14.

Xiao, X., Chang, G., Liu, J., Sun, G., Liu, L., Qin, S., & Zhang, D. (2016). Simvastatin ameliorates ventricular remodeling via the TGF-β1 signaling pathway in rats following myocardial infarction. Molecular Medicine Reports, 13(6), 5093–5101. https://doi.org/10.3892/mmr.2016.5178CrossRefPubMedPubMedCentral

15.

Putu Nita, C. (2019). Effect of simvastatin on histopathology of the heart after 5/6 subtotal nephrectomy. International Journal of Applied Pharmaceutics, 11(5), 131–133. https://doi.org/10.22159/ijap.2019.v11s5.T0105CrossRef

16.

Thabit, A., Alhifany, A., Alsheikh, R., Namnqani, S., Al-Mohammadi, A., Elmorsy, S., Qari, M., & Ardawi, M. (2014). Effect of simvastatin and atorvastatin on serum vitamin D and bone mineral density in hypercholesterolemic patients: A cross-sectional study. Journal of Osteoporosis. https://doi.org/10.1155/2014/468397CrossRefPubMedPubMedCentral

17.

Liu, D., Liu, Y., Yi, Z., & Dong, H. (2016). Simvastatin protects cardiomyocytes from doxorubicin cardiotoxicity by suppressing endoplasmic reticulum stress and activating Akt signaling. International Journal of Clinical Experimental Medicine, 9(2), 2193–2201.

18.

Morse, L. R., Coker, J., & Battaglino, R. A. (2018). Statins and bone health: A mini review. Actualizaciones en Osteologia, 14(1), 31–35.PubMedPubMedCentral

19.

Murphy, C., Deplazes, E., Cranfield, C. G., & Garcia, A. (2020). The role of structure and biophysical properties in the pleiotropic effects of statins. International Journal of Molecular Sciences, 21(8745), 1–29. https://doi.org/10.3390/ijms21228745CrossRef

20.

Atef, M. M., Hafez, Y. M., Alshenawy, H. A., & Emam, M. N. (2019). Ameliorative effects of autophagy inducer, simvastatin on alcohol-induced liver disease in a rat model. Journal of Cellular Biochemistry, 120(5), 7679–7688. https://doi.org/10.1002/jcb.28042CrossRefPubMed

21.

MacDougall, D. A., Pugh, S. D., Bassi, H. S., Lotteau, S., Porter, K. E., & Calaghan, S. (2017). Simvastatin promotes cardiac myocyte relaxation in association with phosphorylation of troponin I. Frontiers in Pharmacology, 8(203), 1–14. https://doi.org/10.3389/fphar.2017.00203CrossRef

22.

Sun, F., Duan, W., Zhang, Y., Zhang, L., Qile, M., Liu, Z., Qiu, F., Zhao, D., Lu, Y., & Chu, W. (2015). Simvastatin alleviates cardiac fibrosis induced by infarction via up-regulation of TGF-β receptor III expression. British Journal of Pharmacology, 172(15), 3779–3792. https://doi.org/10.1111/bph.13166CrossRefPubMedPubMedCentral

23.

Lee, M. M. Y., Sattar, N., McMurray, J. J. V., & Packard, C. J. (2019). Statins in the prevention and treatment of heart failure: A review of the evidence. Current Atherosclerosis Reports, 21(10), 1–8. https://doi.org/10.1007/s11883-019-0800-zCrossRef

24.

Patel, R., Nagueh, S. F., Tsybouleva, N., Abdellatif, M., Lutucuta, S., Kopelen, H. A., Quinones, M. A., Zoghbi, W. A., Entman, M. L., Roberts, R., & Marian, A. J. (2001). Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation, 104(3), 317–324. https://doi.org/10.1161/hc2801.04031CrossRefPubMedPubMedCentral

25.

Skrzypiec-Spring, M., Sapa-Wojciechowska, A., Haczkiewicz-Leśniak, K., Piasecki, T., Kwiatkowska, J., Podhorska-Okołów, M., & Szeląg, A. (2021). Hmg-coa reductase inhibitor, simvastatin is effective in decreasing degree of myocarditis by inhibiting metalloproteinases activation. Biomolecules, 11(10), 1–13. https://doi.org/10.3390/biom11101415CrossRef

26.

Lach, G., Fülling, C., Bastiaanssen, T. F. S., Fouhy, F., O’Donovan, A. N., Ventura-Silva, A. P., Stanton, C., Dinan, T. G., & Cryan, J. F. (2020). Enduring neurobehavioral effects induced by microbiota depletion during the adolescent period. Translational Psychiatry, 10(1), 382. https://doi.org/10.1038/s41398-020-01073-0CrossRefPubMedPubMedCentral

27.

McKay, A., Leung, B. P., McInnes, I. B., Thomson, N. C., & Liew, F. Y. (2004). A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. The Journal of Immunology, 172(5), 2903–2908. https://doi.org/10.4049/jimmunol.172.5.2903CrossRefPubMed

28.

Harash, G., Richardson, K. C., Alshamy, Z., Hünigen, H., Hafez, H. M., Plendl, J., & Masri, S. A. (2019). Heart ventricular histology and microvasculature together with aortic histology and elastic lamellar structure: A comparison of a novel dual-purpose to a broiler chicken line. PLoS ONE, 14(3), 1–20. https://doi.org/10.1371/journal.pone.0214158CrossRef

29.

Baudouy, D., Michiels, J. F., Vukolic, A., Wagner, K. D., & Wagner, N. (2017). Echocardiographic and histological examination of cardiac morphology in the mouse. Journal of Visualized Experiments, 2017(128), 1–9. https://doi.org/10.3791/55843CrossRef

30.

Chen, Y., Yu, Q., & Xu, C. B. (2017). A convenient method for quantifying collagen fibers in atherosclerotic lesions by imagej software. International Journal of Clinical and Experimental Medicine, 10(10), 14904–14910.

31.

Latiff, S., & Olateju, O. I. (2022). Quantification and comparison of tenocyte distribution and collagen content in the commonly used autografts for anterior cruciate ligament reconstruction. Anatomy & Cell Biology, 55(3), 304–310. https://doi.org/10.5115/acb.22.005CrossRef

32.

Balzano, T., Arenas, Y. M., Dadsetan, S., Forteza, J., Gil-Perotin, S., Cubas-Nuñez, L., Casanova, B., Gracià, F., Varela-Andrés, N., Montoliu, C., Llansola, M., & Felipo, V. (2020). Sustained hyperammonemia induces TNF-A in Purkinje neurons by activating the TNFR1-NF-κB pathway. Journal of Neuroinflammation, 17(1), 1–22. https://doi.org/10.1186/s12974-020-01746-zCrossRef

33.

Guo, R., & Ren, J. (2010). Alcohol dehydrogenase accentuates ethanol-induced myocardial dysfunction and mitochondrial damage in mice: Role of mitochondrial death pathway. PLoS ONE, 5(1), 1–10. https://doi.org/10.1371/journal.pone.0008757MathSciNetCrossRef

34.

Lai, Y.-J., Hung, C.-L., Hong, R.-C., Tseng, Y.-M., Lin, C.-I., Ko, Y.-S., Tsai, C.-H., & Yeh, H.-I. (2011). Slow conduction and gap junction remodeling in murine ventricle after chronic alcohol ingestion. Journal of Biomedical Science, 18, 1–9.CrossRef

35.

Law, B. A., Levick, S. P., & Carver, W. E. (2012). Alterations in cardiac structure and function in a murine model of chronic alcohol consumption. Microscopy and Microanalysis, 18(3), 453–461. https://doi.org/10.1017/S1431927612000372CrossRefPubMed

36.

Ai, L., Perez, E., Asimes, A., Kampaengsri, T., Heroux, M., Zlobin, A., Hiske, M. A., Chung, C. S., Pak, T. R., & Kirk, J. A. (2020). Binge alcohol exposure in adolescence impairs normal heart growth. Journal of the American Heart Association, 9(9), 1–12. https://doi.org/10.1161/JAHA.119.015611CrossRef

37.

Coelho-Filho, O. R., Shah, R. V., Mitchell, R., Neilan, T. G., Moreno, H., Simonson, B., Kwong, R., Rosenzweig, A., Das, S., & Jerosch-Herold, M. (2013). Quantification of cardiomyocyte hypertrophy by cardiac magnetic resonance: Implications for early cardiac remodeling. Circulation, 128(11), 1225–1233. https://doi.org/10.1161/CIRCULATIONAHA.112.000438CrossRefPubMedPubMedCentral

38.

Fernandez Sola, J., & Estruch Riba, R. (2017). Alcoholic cardiomyopathy: Old and new insights. Journal of Alcoholism & Drug Dependence, 5(06), 1–6. https://doi.org/10.4172/2329-6488.1000293CrossRef

39.

Kawano, Y. (2010). Physio-pathological effects of alcohol on the cardiovascular system: Its role in hypertension and cardiovascular disease. Hypertension Research, 33(3), 181–191. https://doi.org/10.1038/hr.2009.226CrossRefPubMed

40.

Alleyne, J., & Dopico, A. M. (2021). Alcohol use disorders and their harmful effects on the contractility of skeletal, cardiac and smooth muscles. Advances in Drug and Alcohol Research, 1, 1–18. https://doi.org/10.3389/adar.2021.10011CrossRef

41.

Calabrese, F., Carturan, E., Chimenti, C., Pieroni, M., Agostini, C., Angelini, A., Crosato, M., Valente, M., Boffa, G. M., Frustaci, A., & Thiene, G. (2004). Overexpression of tumor necrosis factor (TNF)-α and TNF–α receptor I in human viral myocariditis: Clinicopathologic correlations. Modern Pathology, 17(9), 1108–1118. https://doi.org/10.1038/modpathol.3800158CrossRefPubMed

42.

Irwin, M. W., Mak, S., Mann, D. L., Qu, R., Penninger, J. M., Yan, A., Dawood, F., Wen, W.-H., Shou, Z., & Liu, P. (1999). Tissue expression and immunolocalization of tumor necrosis factor-in postinfarction dysfunctional myocardium. Circulation, 99(11), 1492–1498.CrossRefPubMed

43.

Lee, J. H., Lee, T.-K., Kim, I. H., Lee, J. C., Won, M.-H., Park, J. H., Ahn, J. H., Shin, M. C., Ohk, T. G., Moon, J. B., Cho, J. H., Park, C. W., & Tae, H.-J. (2017). Changes in histopathology and tumor necrosis factor-α levels in the hearts of rats following asphyxial cardiac arrest. Clinical and Experimental Emergency Medicine, 4(3), 160–167. https://doi.org/10.15441/ceem.17.220CrossRefPubMedPubMedCentral

44.

Li, X., Nie, Y., Lian, H., & Hu, S. (2018). Histopathologic features of alcoholic cardiomyopathy compared with idiopathic dilated cardiomyopathy. Medicine, 97(39), 1–5. https://doi.org/10.1097/MD.0000000000012259CrossRef

45.

Qin, Y. W., Ye, P., He, J. Q., Sheng, L., Wang, L. Y., & Du, J. (2010). Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a western-style diet by increasing PPAR α and γ expression and reducing TC, MMP-9, and Cat S levels. Acta Pharmacologica Sinica, 31(10), 1350–1358. https://doi.org/10.1038/aps.2010.109CrossRefPubMedPubMedCentral

46.

Su, F., Shi, M., Zhang, J., Zheng, Q., Zhang, D., Zhang, W., Wang, H., & Li, X. (2018). Simvastatin protects heart from pressure overload injury by inhibiting excessive autophagy. International Journal of Medical Sciences, 15(13), 1508–1516. https://doi.org/10.7150/ijms.28106CrossRefPubMedPubMedCentral

47.

Chen, Y. Q., Zhao, L. Y., Zhang, W. Z., & Li, T. (2015). Simvastatin reverses cardiomyocyte hypertrophy via the upregulation of phosphatase and tensin homolog expression. Experimental and Therapeutic Medicine, 10(2), 797–803. https://doi.org/10.3892/ETM.2015.2550CrossRefPubMedPubMedCentral

48.

Al-Rasheed, N. M., Al-Oteibi, M. M., Al-Manee, R. Z., Al-Shareef, S. A., Al-Rasheed, N. M., Hasan, I. H., Mohamad, R. A., & Mahmoud, A. M. (2015). Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway. Drug Design, Development and Therapy, 9, 3217–3229. https://doi.org/10.2147/DDDT.S86431CrossRefPubMedPubMedCentral

49.

Ahmed, L. A., Darwish, H. A., Abdelsalam, R. M., & Amin, H. A. A. (2016). Role of rho kinase inhibition in the protective effect of fasudil and simvastatin against 3-nitropropionic acid-induced striatal neurodegeneration and mitochondrial dysfunction in rats. Molecular Neurobiology, 53(6), 3927–3938. https://doi.org/10.1007/s12035-015-9303-2CrossRefPubMed

50.

Refaie, M. M. M., El-Hussieny, M., Bayoumi, A. M. A., Shehata, S., Welson, N. N., & Abdelzaher, W. Y. (2022). Simvastatin cardioprotection in cyclophosphamide-induced toxicity via the modulation of inflammasome/caspase1/interleukin1β pathway. Human and Experimental Toxicology, 41, 1–11. https://doi.org/10.1177/09603271221111440CrossRef

51.

Nežić, L., Škrbić, R., Amidžić, L., Gajanin, R., Kuča, K., & Jaćević, V. (2018). Simvastatin protects cardiomyocytes against endotoxin-induced apoptosis and up-regulates survivin/NF-κB/p65 expression. Scientific Reports, 8(1), 1–18. https://doi.org/10.1038/S41598-018-32376-4CrossRef

52.

Rohilla, A., Ahmad, A., Khan, M. U., & Khanam, R. (2015). A comparative study on the cardioprotective potential of atorvastatin and simvastatin in hyperhomocysteinemic rat hearts. European Journal of Pharmacology, 764, 48–54. https://doi.org/10.1016/J.EJPHAR.2015.06.045CrossRefPubMed

53.

Goldstein, J. L., & Brown, M. S. (1990). Regulation of the mevalonate pathway. Nature, 343(6257), 425–430. https://doi.org/10.1038/343425a0CrossRefPubMed

54.

Segatto, M., Manduca, A., Lecis, C., Rosso, P., Jozwiak, A., Swiezewska, E., Moreno, S., Trezza, V., & Pallottini, V. (2014). Simvastatin treatment highlights a new role for the isoprenoid/cholesterol biosynthetic pathway in the modulation of emotional reactivity and cognitive performance in rats. Neuropsychopharmacology, 39(4), 841–854. https://doi.org/10.1038/npp.2013.284CrossRefPubMed

55.

Fracassi, A., Marangoni, M., Rosso, P., Pallottini, V., Fioramonti, M., Siteni, S., & Segatto, M. (2019). Statins and the brain: More than lipid lowering agents? Current Neuropharmacology, 17(1), 59–83. https://doi.org/10.2174/1570159X15666170703101816CrossRefPubMedPubMedCentral

56.

Luo, J. D., Zhang, W. W., Zhang, G. P., Guan, J. X., & Chen, X. (1999). Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clinical and Experimental Pharmacology and Physiology, 26(11), 903–908. https://doi.org/10.1046/j.1440-1681.1999.03165.xCrossRefPubMed

57.

Scalia, R., Gooszen, M. E., Jones, S. P., Hoffmeyer, M., Rimmer, D. M., III., Trocha, S. D., Huang, P. L., Smith, M. B., Lefer, A. M., & Lefer, D. J. (2001). Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E–deficient mice. Circulation, 103(21), 2598–2603. https://doi.org/10.1161/01.CIR.103.21.2598CrossRefPubMed

58.

Takemoto, M., Node, K., Nakagami, H., Liao, Y., Grimm, M., Takemoto, Y., Kitakaze, M., & Liao, J. K. (2001). Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. The Journal of Clinical Investigation, 108(10), 1429–1437. https://doi.org/10.1172/JCI13350CrossRefPubMedPubMedCentral

59.

Nakagami, H., Jensen, K., & Liao, J. (2003). A novel pleiotropic effect of statins: Prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Annals of Medicine, 35(6), 398–403. https://doi.org/10.1080/07853890310001294CrossRefPubMed

60.

Liu, J., Shen, Q., & Wu, Y. (2008). Simvastatin prevents cardiac hypertrophy in vitro and in vivo via JAK/STAT pathway. Life Sciences, 82(19–20), 991–996. https://doi.org/10.1016/j.lfs.2008.02.012CrossRefPubMed

61.

Zhai, Y., Gao, X., Wu, Q., Peng, L., Lin, J., & Zuo, Z. (2008). Fluvastatin decreases cardiac fibrosis possibly through regulation of TGF-β1/Smad 7 expression in the spontaneously hypertensive rats. European Journal of Pharmacology, 587(1–3), 196–203. https://doi.org/10.1016/j.ejphar.2008.03.006CrossRefPubMed

62.

Blum, A., & Shamburek, R. (2009). The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis, 203(2), 325–330. https://doi.org/10.1016/j.atherosclerosis.2008.08.022CrossRefPubMed

63.

Yamamoto, C., Fukuda, N., Jumabay, M., Saito, K., Matsumoto, T., Ueno, T., Soma, M., Matsumoto, K., & Shimosawa, T. (2011). Protective effects of statin on cardiac fibrosis and apoptosis in adrenomedullin-knockout mice treated with angiotensin II and high salt loading. Hypertension Research, 34(3), 348–353. https://doi.org/10.1038/hr.2010.243CrossRefPubMed

64.

Antonopoulos, S., Margaritis, M. A., Lee, R., Channon, K., & Antoniades, C. (2012). Statins as anti-inflammatory agents in atherogenesis: Molecular mechanisms and lessons from the recent clinical trials. Current Pharmaceutical Design, 18(11), 1519–1530. https://doi.org/10.2174/138161212799504803CrossRefPubMedPubMedCentral

65.

Akahori, H., Tsujino, T., Naito, Y., Matsumoto, M., Sasaki, N., Iwasaku, T., Eguchi, A., Sawada, H., Hirotani, S., & Masuyama, T. (2014). Atorvastatin ameliorates cardiac fibrosis and improves left ventricular diastolic function in hypertensive diastolic heart failure model rats. Journal of Hypertension, 32(7), 1534–1541. https://doi.org/10.1097/HJH.0000000000000184CrossRefPubMed

66.

Kudo, S., Satoh, K., Nogi, M., Suzuki, K., Sunamura, S., Omura, J., Kikuchi, N., Kurosawa, R., Satoh, T., Minami, T., & Ikeda, S. (2016). SmgGDS as a crucial mediator of the inhibitory effects of statins on cardiac hypertrophy and fibrosis: Novel mechanism of the pleiotropic effects of statins. Hypertension, 67(5), 878–889. https://doi.org/10.1161/HYPERTENSIONAHA.115.07089CrossRefPubMed

67.

Oesterle, A., Laufs, U., & Liao, J. K. (2017). Pleiotropic effects of statins on the cardiovascular system. Circulation Research, 120(1), 229–243. https://doi.org/10.1161/CIRCRESAHA.116.308537CrossRefPubMedPubMedCentral

68.

Kuo, H. F., Hsieh, C. C., Wang, S. C., Chang, C. Y., Hung, C. H., Kuo, P. L., Liu, Y. R., Li, C. Y., & Liu, P. L. (2019). Simvastatin attenuates cardiac fibrosis via regulation of cardiomyocyte-derived exosome secretion. Journal of Clinical Medicine, 8(6), 794. https://doi.org/10.3390/jcm8060794CrossRefPubMedPubMedCentral

69.

Koushki, K., Shahbaz, S. K., Mashayekhi, K., Sadeghi, M., Zayeri, Z. D., Taba, M. Y., Banach, M., Al-Rasadi, K., Johnston, T. P., & Sahebkar, A. (2021). Anti-inflammatory action of statins in cardiovascular disease: The role of inflammasome and toll-like receptor pathways. Clinical Reviews in Allergy and Immunology, 60(2), 175–199. https://doi.org/10.1007/s12016-020-08791-9CrossRefPubMed

Title: Simvastatin Significantly Reduced Alcohol-Induced Cardiac Damage in Adolescent Mice
Authors: Makgotso Nchodu
Alice Efuntayo
Robin du Preez
Hasiena Ali
Oladiran I. Olateju
Publication date: 23-01-2024
Publisher: Springer US
Keyword: Simvastatin
Published in: Cardiovascular Toxicology / Issue 1/2024
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-023-09821-6

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Simvastatin Significantly Reduced Alcohol-Induced Cardiac Damage in Adolescent Mice

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Four‑Dimensional Echocardiographic Evaluation of Cardiac Iron Overload in Patients with Beta-Thalassemia Major

Blood Homocysteine Levels Mediate the Association Between Blood Lead Levels and Cardiovascular Mortality

On the Mechanisms of the Cardiotoxic Effect of Lead Oxide Nanoparticles

Human Immunodeficiency Virus as a Risk Factor for Cardiovascular Disease

Arsenic-Induced Cardiovascular Diseases and their Correlation with Mitochondrial DNA Copy Number, Deletion, and Telomere Length in Bangladeshi Population

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page